NRx Pharmaceuticals (NRXP) Stock Analysis

What NRx Pharmaceuticals does

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Key metrics

ETFs linked to NRXP

Broad-market and Healthcare sector ETFs an investor holding NRx Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NRXP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NRx Pharmaceuticals?

NRx Pharmaceuticals trades under the ticker NRXP on NASDAQ.

Which exchange is NRXP listed on?

NRXP is listed on NASDAQ.

What sector does NRx Pharmaceuticals operate in?

NRx Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NRXP in a portfolio?

PortView shows NRXP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.